Pre-Surgical Combination Therapy Enhances Survival in Rare Thyroid Cancer Patients
Combining pembrolizumab with targeted therapies significantly improves survival and surgical resection rates in patients with aggressive BRAF-mutated anaplastic thyroid cancer.
A recent study from The University of Texas MD Anderson Cancer Center has demonstrated that a pre-surgical combination treatment involving pembrolizumab, dabrafenib, and trametinib significantly improves outcomes in patients with BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC). This Phase II multicenter trial revealed that adding immunotherapy to targeted therapies not only increased the likelihood of tumor resection, with 74% of patients able to undergo surgery compared to just 5% with previous treatments, but also extended overall survival from an average of 14.5 to 18 months.
Anaplastic thyroid cancer is known for its aggressive nature, often presenting with tumors that are difficult to remove surgically. The study’s lead investigator, Dr. Mark Zafereo, noted that traditional treatments offered limited benefits, typically extending survival by only a few months. In contrast, incorporating pembrolizumab, an immunotherapy agent, alongside dabrafenib and trametinib—which inhibit the mutant BRAF protein—enabled better disease control.
Patients enrolled in the study between September 2021 and January 2025 received a median of four therapy cycles before surgery, with 30 out of 40 patients undergoing tumor removal. The combination therapy also doubled the progression-free survival, from approximately 6.7 months to over a year, indicating a delay in cancer progression.
While side effects such as kidney injury, sepsis, and intestinal tear were observed, the results suggest that this approach could become a new standard of care for BRAFm-ATC, especially for patients with the specific BRAF mutation. The study’s limitations include its small size, lack of a control group, and limited follow-up duration.
This research underscores the potential of combining immunotherapy with targeted treatments to improve surgical outcomes and prolong survival in aggressive thyroid cancers. Further studies are needed to confirm these findings and establish long-term benefits.
Source: https://medicalxpress.com/news/2025-06-pre-surgical-combination-therapy-boosts.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Four-Drug Regimen Sets New Standard for Treating Multiple Myeloma
A groundbreaking clinical trial introduces a new four-drug combination that significantly improves outcomes for patients with newly diagnosed multiple myeloma, establishing a fresh standard of care.
Innovative Zebrafish Study Offers Hope for Rare Lymphatic Disease Treatment
A groundbreaking study using zebrafish models uncovers potential drugs to treat kaposiform lymphangiomatosis (KLA), a rare lymphatic disorder, offering hope for faster, safer therapies.
Study Finds Urban Missouri Areas Have Higher Prescriptions of High-Dose Opioids
A recent study reveals that urban areas in Missouri have higher rates of high-dose opioid prescriptions, increasing risks for opioid use disorder among residents. The research emphasizes demographic and regional factors influencing prescribing habits.
New Genetic Discovery Offers Hope for Chronic Pain Treatment
Researchers have identified a new genetic factor involved in chronic pain, revealing a promising target for innovative pain therapies that could reduce reliance on opioids. The discovery centers around the SLC45A4 gene, which encodes a neuronal polyamine transporter, offering new hope for safe and effective pain management.